MXPA05010214A - Sistemas de sintasa de poliquetida pufa y uso de los mismos. - Google Patents

Sistemas de sintasa de poliquetida pufa y uso de los mismos.

Info

Publication number
MXPA05010214A
MXPA05010214A MXPA05010214A MXPA05010214A MXPA05010214A MX PA05010214 A MXPA05010214 A MX PA05010214A MX PA05010214 A MXPA05010214 A MX PA05010214A MX PA05010214 A MXPA05010214 A MX PA05010214A MX PA05010214 A MXPA05010214 A MX PA05010214A
Authority
MX
Mexico
Prior art keywords
pufa
systems
polykettide
pufa pks
same
Prior art date
Application number
MXPA05010214A
Other languages
English (en)
Spanish (es)
Inventor
James H Flatt
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Publication of MXPA05010214A publication Critical patent/MXPA05010214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
MXPA05010214A 2003-03-26 2004-03-26 Sistemas de sintasa de poliquetida pufa y uso de los mismos. MXPA05010214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45797903P 2003-03-26 2003-03-26
PCT/US2004/009323 WO2004087879A2 (en) 2003-03-26 2004-03-26 Pufa polyketide synthase systems and uses thereof

Publications (1)

Publication Number Publication Date
MXPA05010214A true MXPA05010214A (es) 2005-12-14

Family

ID=33131738

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA05010214A MXPA05010214A (es) 2003-03-26 2004-03-26 Sistemas de sintasa de poliquetida pufa y uso de los mismos.
MX2011000195A MX341785B (es) 2003-03-26 2004-03-26 Sistemas de sintasa de poliquetida pufa y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011000195A MX341785B (es) 2003-03-26 2004-03-26 Sistemas de sintasa de poliquetida pufa y uso de los mismos.

Country Status (11)

Country Link
EP (1) EP1623008B1 (https=)
JP (3) JP2007524377A (https=)
KR (3) KR101234199B1 (https=)
CN (1) CN101389213B (https=)
AU (2) AU2004225485B2 (https=)
BR (1) BRPI0409046A (https=)
CA (1) CA2520396C (https=)
ES (1) ES2516641T3 (https=)
IL (1) IL200625A0 (https=)
MX (2) MXPA05010214A (https=)
WO (1) WO2004087879A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
US6566583B1 (en) 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US8003772B2 (en) * 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
US7217856B2 (en) 1999-01-14 2007-05-15 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7211418B2 (en) 1999-01-14 2007-05-01 Martek Biosciences Corporation PUFA polyketide synthase systems and uses thereof
US7247461B2 (en) 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
EP2960325B1 (en) 2000-01-28 2017-09-27 DSM IP Assets B.V. Enhanced production of lipids containing polyenoic fatty acids by high density cultures of eukaryotic microbes in fermentors
AU2006265801B2 (en) 2005-07-01 2011-07-14 Martek Biosciences Corporation Polyunsaturated fatty acid-containing oil product and uses and production thereof
GB0603160D0 (en) * 2006-02-16 2006-03-29 Rothamsted Res Ltd Nucleic acid
KR101524398B1 (ko) 2006-03-15 2015-06-04 디에스엠 아이피 어셋츠 비.브이. Ｐｕｆａ 폴리케티드 신타제 시스템을 이용한 이종 생물체내 다불포화 지방산의 제조
WO2008027991A2 (en) * 2006-08-29 2008-03-06 Martek Biosciences Corporation USE OF DPA(n-6) OILS IN INFANT FORMULA
EP2405018A4 (en) * 2009-03-04 2013-02-20 Univ Miyazaki METHOD FOR DETERMINING THE FATTY ACID SYNTHESIS PATH OF A MICROORGANISM AND PCR PRIMER FOR THIS METHOD
CN104263729B (zh) 2009-03-16 2020-09-15 帝斯曼知识产权资产有限公司 在网粘菌门微生物中产生蛋白质
ES2717102T3 (es) 2009-03-19 2019-06-19 Dsm Ip Assets Bv Moléculas de ácido nucleico de ácido graso poliinsaturado sintasas, y polipéptidos, composiciones y métodos de preparación y usos de los mismos
EP2614829A1 (en) * 2012-01-11 2013-07-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons
KR101570771B1 (ko) 2013-11-18 2015-11-23 대한민국 고도불포화지방산 생합성을 위한 재조합 벡터 및 이를 이용하여 제작된 형질전환 식물체
JP6682109B2 (ja) * 2015-01-09 2020-04-15 国立大学法人 宮崎大学 ヤブレツボカビ類を用いたリグニン分解活性を有するタンパク質の製造方法
CN109477079A (zh) * 2016-05-12 2019-03-15 帝斯曼知识产权资产管理有限公司 增加微藻中ω-3多不饱和脂肪酸产量的方法
US11613728B2 (en) 2018-08-10 2023-03-28 Kyowa Hakko Bio Co., Ltd. Microorganism producing eicosapentaenoic acid and method for producing eicosapentaenoic acid
US12241101B2 (en) 2018-08-10 2025-03-04 Kyowa Hakko Bio Co., Ltd. Microorganism producing polyunsaturated fatty acid and method for producing polyunsaturated fatty acid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340742A (en) * 1988-09-07 1994-08-23 Omegatech Inc. Process for growing thraustochytrium and schizochytrium using non-chloride salts to produce a microfloral biomass having omega-3-highly unsaturated fatty acids
BR9809946A (pt) * 1997-06-04 2000-08-01 Calgene Llc Produção de ácidos graxos poliinsaturados por expressão de genes de sìntese semelhantes a policetìdeo em plantas
US6566583B1 (en) * 1997-06-04 2003-05-20 Daniel Facciotti Schizochytrium PKS genes
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US7247461B2 (en) * 1999-01-14 2007-07-24 Martek Biosciences Corporation Nucleic acid molecule encoding ORFA of a PUFA polyketide synthase system and uses thereof
CN101845446B (zh) * 2000-09-28 2016-01-20 生物源食物及科学公司 脂肪酸去饱和酶家族成员fad4、fad5、fad5-2和fad6及它们的应用
TWI426126B (zh) * 2001-04-16 2014-02-11 Dsm Ip Assets Bv 多不飽和脂肪酸（ｐｕｆａ）聚乙醯合成酶系統及其用途（二）
EP1390507A2 (en) * 2001-05-21 2004-02-25 Ecopia Biosciences Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures

Also Published As

Publication number Publication date
AU2008249169A1 (en) 2008-12-11
EP1623008A2 (en) 2006-02-08
CA2520396C (en) 2016-08-09
WO2004087879A3 (en) 2008-07-24
KR20060006014A (ko) 2006-01-18
KR20120123726A (ko) 2012-11-09
JP6134361B2 (ja) 2017-05-24
KR101234198B1 (ko) 2013-02-19
KR20120097502A (ko) 2012-09-04
AU2008249169B2 (en) 2012-03-15
CA2520396A1 (en) 2004-10-14
JP2013143945A (ja) 2013-07-25
CN101389213B (zh) 2014-05-28
BRPI0409046A (pt) 2006-04-18
ES2516641T3 (es) 2014-10-31
CN101389213A (zh) 2009-03-18
AU2004225485B2 (en) 2008-08-21
JP2016000048A (ja) 2016-01-07
MX341785B (es) 2016-09-01
EP1623008A4 (en) 2009-05-27
EP1623008B1 (en) 2014-07-30
IL200625A0 (en) 2011-07-31
KR101234199B1 (ko) 2013-02-20
HK1088632A1 (en) 2006-11-10
AU2004225485A1 (en) 2004-10-14
KR101234200B1 (ko) 2013-02-19
JP5890791B2 (ja) 2016-03-22
JP2007524377A (ja) 2007-08-30
WO2004087879A2 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
MXPA05010214A (es) Sistemas de sintasa de poliquetida pufa y uso de los mismos.
BRPI0516327A (pt) sistemas de policetìdeo sintase de pufa e usos dos mesmos
AR118722A2 (es) Proteínas tóxicas para especies de insectos hemípteros
ZA202007843B (en) Tertiary amine substituted coumarin compounds and their uses as fluorescent labels
AR114014A1 (es) Sistema de edición de bases y método basado en proteína cpf1
ES2690386T3 (es) Composición para escindir un ADN diana que comprende un ARN guía específico para el ADN diana y el ácido nucleico que codifica la proteína Cas o la propia proteína Cas, y sus usos
EP4257596A3 (en) Coumarin compounds and their uses as fluorescent labels
MX2012013037A (es) Composiciones de endorribonucleasa y metodos de uso de las mismas.
MX2020013384A (es) Compuestos de comarina sustituidos con amina exocíclica y sus usos como etiquetas fluorescentes.
UY34227A (es) Acido nucleico recombinante que codifica el gen de la toxina axmi270, vectores, células, plantas y sus métodos de empleo
AR122864A2 (es) Variantes de lipasa y polinucleótidos que las codifican
BR112012028049A2 (pt) organismo microbiano de ocorrência não natural e método para produzir butadieno, meio de cultura, butadieno biossintetizado, composição, produto químico orgânico, polímero e uso de butadieno biossintetizado
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
CL2009000879A1 (es) Metodo para fabricar un producto en un biorreactor que comprende cultivar microorganismos que son adaptados o mutagenizados para que exhiban por lo menos un 150% de tolerancia al producto; sistema para fabricar un producto; biorreactor.
CO6470854A2 (es) Variantes de celulasa con expresión, actividad y/o estabilidad mejoradas, y uso de las mismas
CL2022002779A1 (es) Compuestos y métodos para modular el proceso de corte y empalme
BR112015005674A2 (pt) variantes e métodos de uso de hppd
CL2011001296A1 (es) Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales.
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
CL2012000558A1 (es) Metodo para controlar malezas en un campo que comprende cultivar una planta y aplicarle un inhibidor de la acetil coa carboxilasa al que la planta es tolerante; y molecula de acido nucleico que codifica dicha enzima modificada.
WO2013181433A3 (en) Plant phenometrics systems and methods and devices related thereto
BR112012018620A2 (pt) organismo microbiano de ocorrência não-natural, método para produzir (2-hidroxi-3-metil-4-oxobutoxi) fosfonato, método para produção de p-toluato, método para produzir tereftalato
MX2018007325A (es) Promotor de catalasa modificado bidireccional de bacilo.
DOP2013000270A (es) Cepas de salmonella gallinarum modificadas avirulentas y composiciones farmacéuticas que las usan

Legal Events

Date Code Title Description
FG Grant or registration